Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Modification of immunomodulatory medications by rheumatology patients during the peak of the COVID-19 pandemic in New York City

Clinical Rheumatology(2022)10.1007/s10067-022-06203-1Source: DataRank Database

Modification of immunomodulatory medications by rheumatology patients during the peak of the COVID-19 pandemic in New York City is a research paper published in Clinical Rheumatology (2022). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 0.00)OA: bronzeTopics (27)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Marianna B. Frey ORCID,Jonah M. Levine ORCID,G. Vitone ORCID,Lindsay Lally,Michael D. Lockshin ORCID

Live enrichment

PubMed:35596096 PMC:PMC9122542 OpenAlex:https://openalex.org/W4281250635

Rheumatology Research Foundation

Grant: Investigator Award

NCATS NIH HHS

Grant: UL1 TR002384

Pfizer

Barbara Volcker Center for Women and Rheumatic Diseases at Hospital for Special Surgery

Regeneron Pharmaceuticals

Bristol-Myers Squibb

National Institutes of Health

Brigham and Women's

FWCI

0.00

Citation Percentile

0.1%

bronzeLicense: https://www.springer.com/tdm

journalhttps://link.springer.com/content/pdf/10.1007/s10067-022-06203-1.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s10067-022-06203-1.pdf

publisherhttps://link.springer.com/article/10.1007/s10067-022-06203-1/fulltext.html

journalhttps://doi.org/10.1007/s10067-022-06203-1

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35596096

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesAutoimmune and Inflammatory Disorders ResearchCOVID-19HumansNew York CityPandemicsRheumatologySARS-CoV-2

MeSH Terms

COVID-19SARS-CoV-2HumansNew York CityRheumatologyPandemics

Keywords

MedicineRheumatologyPandemicCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Internal medicineFamily medicineVirologyDiseaseInfectious disease (medical specialty)Outbreak

Sustainable Development Goals

SDG 0: Good health and well-being